Clinical Trial Update: SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SBRT with CAPEOX chemotherapy, bevacizumab, and a PD-1 inhibitor for unresectable, microsatellite-stable, RAS-mutant metastatic colorec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab) (bevacizumab)
• Eloxatin (oxaliplatin) (oxaliplatin)
• PD-1 inhibitor
• Xeloda (capecitabine) (capecitabine)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Phase 2 | Status: NOT_YET_RECRUITING